Author | Hayley Virgil | OncLive

Author | Hayley Virgil


Adjuvant T-DM1 Shows Consistent Benefit in Residual Invasive HER2+ Breast Cancer, Irrespective of Mutational Status

August 14, 2020


Ado-trastuzumab emtansine demonstrated a consistent invasive disease-free survival benefit versus trastuzumab in patients with HER2-positive breast cancer across all biomarker subgroups evaluated in the pivotal phase 3 KATHERINE trial.

TP53 Mutation Status Possesses Prognostic Implications in MDS

August 14, 2020


Patients with myelodysplastic syndromes who have biallelic TP53 have worse outcomes, such as treatment-resistant disease, rapid disease progression, and low overall survival, versus those with monoallelic mutations.

Combination Biomarker Is Predictive of Response to Immunotherapy in Metastatic Urothelial Carcinoma

August 13, 2020


The combination of ARID1A mutations and the immune signaling protein CXCL13 proved to be predictive of clinical response and prolonged survival after treatment with checkpoint inhibitors in patients with metastatic urothelial carcinoma.

Stronger Racial and Ethnic Minority Presence Is Needed in Clinical Cancer Trials

August 12, 2020


Numerous analyses conducted over the past few years have underscored a serious issue in clinical cancer trials that needs to be addressed: a lack of racial and ethnic diversity among participants.